BPX-701 / Leiden University Medical Center, Bellicum - LARVOL DELTA

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma (clinicaltrials.gov) - P1/2 | N=4 | Terminated | Sponsor: Bellicum Pharmaceuticals | N=28 ➔ 4 | Unknown status ➔ Terminated; company decision

Enrollment change • Metastases • Trial termination • Acute Myelogenous Leukemia • Eye Cancer • Hematological Malignancies • Leukemia • Melanoma • Myelodysplastic Syndrome • Oncology • Solid Tumor • Uveal Melanoma • PRAME

"Other PRAME-directed eTCR projects beyond $IMTX IMA203: I see $GSK, $MDGEF (MDG1011) & $BLCM (BPX-701!). Any others?" (@JacobPlieth)

PRAME

"you may want to add the most likely $BLCM merger candidates beside $ADAP for BPX-701 (speculation 3rd target for $GSK): $IMTX Immatics joint venture with @MDAndersonNews also 4 CAR-NK with Takeda" (@dhovekamp42)

"Ok,so far BPX-701 (correct me if im wrong @dhovekamp42)could help us clear some things up over switchers $BLCM $CLLS https://t.co/PigNZAUJpH" (@BursatilBiotech)

Biosimilar

"Sloth speeding up Ph1 BPX-701's enrollment? Jaja I love you, $BLCM You're so cute sometimes" (@BursatilBiotech)

Biosimilar

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma (clinicaltrials.gov) - P1/2; N=28; Active, not recruiting; Sponsor: Bellicum Pharmaceuticals; Trial completion date: Dec 2019 ➔ Jul 2020; Trial primary completion date: Dec 2019 ➔ Jul 2019

Clinical • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Melanoma • Myelodysplastic Syndrome • Ocular Melanoma • Oncology • Solid Tumor

"Medigene sold Asian rights for similar technique in a bundle with TCRs like the Bellicum BPX-701 for $1Bln BioBucks to RoiVant https://t.co/GKdYI2u8Xb" (@dhovekamp42)

"Rivo-cel or BPX-701 deal partnering perhaps ?" (@dhovekamp42)

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma (clinicaltrials.gov) - P1/2; N=28; Active, not recruiting; Sponsor: Bellicum Pharmaceuticals; Recruiting ➔ Active, not recruiting; N=116 ➔ 28

Clinical • Enrollment change • Enrollment closed

"Thanks - Rick could you comment on $BLCM BPX-701 ? https://t.co/vKUBSJWr7f" (@dhovekamp42)